Clinical Trial Update: Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiation with nimotuzumab in elderly patients with locoregionally advanced nasopharyngeal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: COMPLETED